Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations
- 1 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (15) , 2091-2094
- https://doi.org/10.1097/00002030-200410210-00017
Abstract
We examined the influence of both efavirenz plasma concentrations and non-nucleoside reverse transcriptase (NNRTI) resistance mutations on the antiviral activity of efavirenz in patients experiencing early virological failure under nevirapine-containing regimens. Up to 41% of patients reach less than 50 copies/ml at 48 weeks. No association was found between the presence of NNRTI resistance mutations and virological outcome. Nevertheless, patients responding virologically and carrying NNRTI-resistant viruses had higher efavirenz levels than those who did not respond.Keywords
This publication has 6 references indexed in Scilit:
- Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine FailureAIDS Research and Human Retroviruses, 2002
- High-Performance Liquid Chromatographic Method for the Simultaneous Determination of the Six HIV-Protease Inhibitors and Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human PlasmaTherapeutic Drug Monitoring, 2002
- Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor TherapyJournal of Virology, 2001
- Clinical Use of Genotypic and Phenotypic Drug Resistance Testing to Monitor Antiretroviral ChemotherapyClinical Infectious Diseases, 2001
- Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsAIDS, 2001
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999